Yes, lung cancer can be surgically removed, and for early-stage disease, surgery offers the best chance of a cure. The five-year survival rate for localized lung cancer that hasn’t spread beyond the lung is 64%, according to National Cancer Institute data. Whether removal is an option for you depends on the cancer’s stage, its location, your lung function, and the specific type of lung cancer involved.
Which Stages Can Be Removed
Surgery is the standard treatment for stage I and stage II non-small cell lung cancer (NSCLC), which accounts for roughly 85% of all lung cancers. At these stages, the tumor is confined to the lung or nearby lymph nodes, and the goal of surgery is a complete cure. Stage I patients, in particular, have the strongest outcomes: surgery provides superior survival and disease control compared to any other treatment option at this stage.
Stage III is more complex. When the cancer has spread to lymph nodes in the center of the chest but is still considered “resectable,” surgery plays a significant role alongside chemotherapy and sometimes radiation. About 20% of all lung cancer cases in the U.S. fall into the unresectable stage III category, where the spread is too extensive for surgery alone but other treatments can still extend life or, in some cases, convert the cancer to a surgically treatable state. If cancer has reached lymph nodes on the opposite side of the chest (called N3 disease), surgery is not offered.
Stage IV lung cancer, where the disease has metastasized to distant organs, is generally not treated with surgery. One exception is “oligometastatic” disease, where only a small number of metastases exist in limited locations. In these select cases, removing the primary lung tumor may still provide benefit, though this isn’t considered curative.
Types of Surgery
The most common operation is a lobectomy, which removes the entire lobe of the lung containing the tumor. (Your right lung has three lobes; your left has two.) Lobectomy has been the preferred approach since the 1960s because it removes a generous margin of tissue around the cancer while preserving enough lung for normal breathing. For most patients with operable lung cancer, this is the go-to procedure.
For smaller tumors (2 cm or less), surgeons may recommend a more limited operation. A wedge resection removes just the tumor and a small rim of surrounding tissue. A segmentectomy removes a larger defined section of a lobe. Both preserve more lung tissue, which matters for people with reduced lung function. Clinical trial data shows that for tumors under 2 cm, these smaller operations achieve similar overall survival to lobectomy, though the chance of cancer recurring in the same area is slightly higher (around 7% versus 4% for lobectomy). Segmentectomy offers better local control than wedge resection, making it the preferred limited option when feasible.
A pneumonectomy, the removal of an entire lung, is reserved for large or centrally located tumors that can’t be addressed with a lobectomy. It’s a more demanding operation with higher risks, so surgeons avoid it when possible.
Minimally Invasive Approaches
Most lung cancer surgeries today are performed using minimally invasive techniques rather than traditional open surgery, which requires a large chest incision. Video-assisted thoracoscopic surgery (VATS) uses small incisions and a camera to guide the operation. Compared to open surgery, VATS results in less pain, less blood loss, fewer complications like pneumonia and irregular heart rhythms, shorter hospital stays, and faster recovery. Long-term survival outcomes are also improved.
Robotic-assisted surgery takes a similar approach but gives the surgeon enhanced precision through robotic instruments. Both robotic and VATS procedures result in lower complication rates than open thoracotomy, and current guidelines support minimally invasive lobectomy as the evidence-based standard when the tumor’s size and location allow it.
What About Small Cell Lung Cancer?
Small cell lung cancer (SCLC) is a faster-growing type that makes up about 15% of cases, and surgery is rarely part of the treatment plan. Only about 5% of SCLC patients are diagnosed early enough (stage I, with no lymph node involvement) for surgery to be considered. For those who do qualify, lobectomy with removal of nearby lymph nodes is the standard operation, and five-year survival ranges from 36% to 63% when combined with chemotherapy. Smaller resections like wedge procedures are not considered appropriate for SCLC. In all cases, surgery is just one part of a multi-treatment approach that includes chemotherapy and sometimes radiation.
Who Is Physically Fit Enough for Surgery
Even if the cancer is at a surgically treatable stage, your lungs need to be healthy enough to function well after losing tissue. Before surgery, you’ll undergo breathing tests called pulmonary function tests. The key measurement is how much air you can forcefully exhale in one second (FEV1). If your result is above 80% of the predicted value for someone your age and size, you’re considered low risk. Between 40% and 80%, you’ll need additional testing to see if you can tolerate the operation. Below 40%, the risk of serious complications rises significantly, including prolonged time on a ventilator and long-term oxygen dependence.
A second measurement looks at how efficiently your lungs transfer oxygen into your blood (DLCO). A result below 40% of predicted is a strong predictor of respiratory failure after surgery. For patients who perform well on exercise tests, newer guidelines lower that cutoff to 30%, reflecting improvements in surgical techniques and post-operative care.
Radiation as an Alternative to Surgery
For people who can’t tolerate surgery due to poor lung function or other health conditions, stereotactic body radiotherapy (SBRT) offers a non-surgical way to target and destroy a tumor. SBRT delivers highly focused, high-dose radiation over just a few sessions. For early-stage lung cancer, local control rates with SBRT range from 87% to 98% at two years.
Head-to-head comparisons show that local control (keeping the cancer from regrowing in the same spot) is broadly similar between SBRT and surgery. However, lobectomy still holds a modest advantage in overall survival and cancer-specific survival. This likely reflects the fact that surgery also removes lymph nodes for staging and catches microscopic spread that imaging can miss. For patients who are surgical candidates, lobectomy remains the stronger option. For those who aren’t, SBRT is a highly effective alternative, not a compromise.
Recurrence After Removal
Complete surgical removal doesn’t guarantee the cancer won’t return. Among patients with stage I or II NSCLC who had all visible cancer removed, the five-year recurrence rate is about 20%. The majority of these recurrences, roughly 82%, appear at distant sites like the brain, bones, or liver rather than back in the lung. Distant recurrence carries a poor prognosis, which is why many patients receive chemotherapy or targeted therapy after surgery to reduce this risk.
Recurrence risk is one reason follow-up imaging after surgery is so important. Most recurrences happen within the first two to three years, so monitoring is most intensive during that window. Your cancer team will typically schedule regular CT scans to catch any return early, when additional treatment is most likely to help.